Cargando…
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism
BACKGROUND: CD137 (4-1BB) is an immune costimulatory receptor with high therapeutic potential in cancer. We are creating tumor target-dependent CD137 agonists using a novel chemical approach based on fully synthetic constrained bicyclic peptide (Bicycle®) technology. Nectin-4 is overexpressed in mul...
Autores principales: | Hurov, Kristen, Lahdenranta, Johanna, Upadhyaya, Punit, Haines, Eric, Cohen, Heather, Repash, Elizabeth, Kanakia, Drasti, Ma, Jun, Kristensson, Julia, You, Fanglei, Campbell, Carly, Witty, David, Kelly, Mike, Blakemore, Stephen, Jeffrey, Phil, McDonnell, Kevin, Brandish, Philip, Keen, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562524/ https://www.ncbi.nlm.nih.gov/pubmed/34725211 http://dx.doi.org/10.1136/jitc-2021-002883 |
Ejemplares similares
-
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
por: Upadhyaya, Punit, et al.
Publicado: (2021) -
Discovery and
Optimization of a Synthetic Class of
Nectin-4-Targeted CD137 Agonists for Immuno-oncology
por: Upadhyaya, Punit, et al.
Publicado: (2022) -
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
por: Rigby, Michael, et al.
Publicado: (2022) -
The bicycle man /
por: Dudley, David L.
Publicado: (2005) -
The Bicycle in Surgery
Publicado: (1898)